Abstract Details

Title Impact of OnabotulinumtoxinA on Quality of Life, Health Resource Utilization, and Work Productivity in People With Chronic Migraine: Interim Results From a Prospective, Observational Study (PREDICT)

Topic Headache

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-023

Objective To assess long-term health-related quality of life (QoL) in people treated with onabotulinumtoxinA for chronic migraine (CM).

Background CM can impair health-related QoL and daily functioning, resulting in social and economic burden.

Design/Methods

Canadian multicentre, prospective, observational study in adults with CM, botulinum toxin naïve for migraine (NCT02502123). Based on the Canadian onabotulinumtoxinA product monograph (July 7, 2014), 7 onabotulinumtoxinA treatments were administered post-baseline/screening. This interim analysis includes data from patients who completed 4 treatment sessions (Tx4; ~10 months). Endpoints: Mean change from baseline to Tx4 in Migraine-Specific Quality of Life (MSQ) score (primary); healthcare resource utilization and work productivity (secondary).

Results Patients at baseline (n=196), post-Tx2 (n=173), and post-Tx4 (n=137) received a mean onabotulinumtoxinA dose of 170.4 U (SD=17.2) per session with a mean interval of 13.1 weeks (SD=1.7) between sessions at this interim analysis. OnabotulinumtoxinA treatment significantly (P<0.0001) increased MSQ scores from baseline to post-Tx4 across all role function domains (restrictive: 36.7 vs 59.8; preventive: 51.4 vs 71.3; emotional: 38.0 vs 63.6; respectively). The percent of patients decreased from baseline to post-Tx2 and post-Tx4 for those who visited an emergency room (17.3%; 9.3%; 6.6%), were admitted to the hospital (3.6%; 2.9%; 1.5%), and received headache-related diagnostic testing (35.9%; 15.9; 8.1%). The percent of patients employed at baseline (73.5%) was similar post-Tx4 (72.3%), while actual hours worked increased slightly from baseline to post-Tx4 (28.0 [SD=15.4]; 29.4 [SD=16.0]) and work hours missed due to headache decreased (5.9 [SD=9.5]; 2.5 [SD=5.9]). Patients reported less impact from headache on work productivity from baseline to post-Tx4 (5.4 [SD=2.1] vs 3.9 [SD=2.6]) and on their ability to perform daily activities (6.1 [SD=2.1] vs 4.2 [SD=2.8]). No new safety signals were identified.

Conclusions This interim analysis demonstrated that onabotulinumtoxinA for CM improved health-related QoL and work productivity and reduced healthcare resource utilization.

Authors/Disclosures
Goran Davidovic, MD PRESENTER	No disclosure on file
	No disclosure on file
Werner J. Becker, MD (Foothills Hospital)	Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Discussion moderator / speaker with Pfizer. Dr. Becker has a non-compensated relationship as a Board Member with Migraine Canada that is relevant to AAN interests or activities. Dr. Becker has a non-compensated relationship as a Board Member with Pain Society of Alberta that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Suzanne N. Christie, MD (Nepean Medical Centre)	No disclosure on file
Meetu Bhogal, MSc (Allergan, Inc.)	No disclosure on file

��ɫ��

��ɫ��